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Abstract
 
Class I and class II MHC-restricted T cells specific for proteins present in myelin have been
shown to be involved in autoimmunity in the central nervous system (CNS). It is not yet
known whether CD1d-restricted T cells reactive to myelin-derived lipids are present in the
CNS and might be targeted to influence the course of autoimmune demyelination. Using specific
glycolipid-CD1d tetramers and cloned T cells we have characterized a T cell population reactive
to a myelin-derived glycolipid, sulfatide, presented by CD1d. This population is distinct from
the invariant V
 
 
 
14
 
 
 
 NK T cells, and a panel of V
 
 
 
3/V
 
 
 
8
 
 
 
 CD1d-restricted NK T cell hybridomas
is unable to recognize sulfatide in the presence of CD1d
 
 
 
 antigen-presenting cells. Interestingly,
during experimental autoimmune encephalomyelitis a model for human multiple sclerosis, sulfatide-
reactive T cells but not invariant NK T cells are increased severalfold in CNS tissue. Moreover,
treatment of mice with sulfatide prevents antigen-induced experimental autoimmune encepha-
lomyelitis in wild-type but not in CD1d-deficient mice. Disease prevention correlates with the
ability of sulfatide to suppress both interferon-
 
 
 
 and interleukin-4 production by pathogenic
myelin oligodendrocyte glycoprotein-reactive T cells. Since recognition of sulfatide by CD1d-
restricted T cells has now been shown both in mice and humans, study of murine myelin lipid-
reactive T cells may form a basis for the development of intervention strategies in human
autoimmune demyelinating diseases.
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Introduction
 
The discovery of CD1-dependent antigen presentation
pathways has provided a mechanism by which T cells can
also recognize lipid antigens (1–3). CD1 molecules are
MHC class I–like, 
 
 
 
2-microglobulin–associated nonpoly-
morphic proteins that can be categorized into two groups:
group 1, comprised of CD1a, CD1b, and CD1c, is present
in humans; and group 2, the CD1d molecule, is present in
most species examined so far (4, 5). Crystal structures of
CD1d and CD1b molecules have revealed a deep hydro-
phobic groove well suited for the binding of long alkyl
chains of amphipathic lipids and thus allow carbohydrate
or other hydrophilic residues of the lipid to interact with
the TCR (6, 7). Consistent with this, crystal structure of
CD1a complexed with sulfatide suggests binding of the
sphingosine and fatty acid chains within the hydrophobic
grooves with the exposed head group available for TCR
recognition (8). CD1-reactive T cells are thought to be
diverse and include the invariant population that uses
conserved CDR3 regions, V
 
 
 
14-J
 
 
 
18
 
 
 
 in mice and
V
 
 
 
24-J
 
 
 
15
 
 
 
 in humans (3, 9, 10). Most of the detailed
understanding of the phenotype, development, and modu-
lation of immune responses by lipid-reactive T cells has
been derived from the use of a surrogate antigen, the marine
sponge-derived glycolipid, 
 
 
 
-galactosyl ceramide (
 
 
 
-GalCer),
which is recognized by the invariant NK T cell population
in the context of CD1d molecules. Unlike 
 
 
 
-GalCer,
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encephalomyelitis; GalCer, galactosyl ceramide; MBP, myelin basic protein;
MS, multiple sclerosis. 
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most mammalian glycolipids have the carbohydrate moiety
attached in a 
 
 
 
-linkage.
CD1d-restricted T cells are thought to be self-reactive,
but with the exception of two studies, one suggesting rec-
ognition of phospholipids (11) and another indicating ex-
pansion of T cells reactive to a tumor-derived GD3 mole-
cule (12), self-glycolipids that stimulate CD1d-reactive T
cells have not been described. In an attempt to characterize
the phenotype and function of mammalian self-glycolipid–
reactive T cells, we have focused on myelin in the nervous
system for several reasons. It is rich in glycolipids that are
formed from a common precursor ceramide that has a po-
tential CD1d-binding domain similar to the well-charac-
terized 
 
 
 
-GalCer. One fifth of the total galactolipid in my-
elin occurs in the form of sulfatide (or 3
 
 
 
-sulfogalactosyl
ceramide) in which the 3
 
 
 
-OH moiety on the galactose is
sulfated. Furthermore, sulfatide has been shown to be a
promiscuous CD1 ligand and can be presented by human
CD1a, CD1b, and CD1c molecules (13). The myelin
sheath is the target of an autoimmune inflammatory process
in multiple sclerosis (MS) (14) and in its animal model ex-
perimental autoimmune encephalomyelitis (EAE), which is
characterized by inflammation and demyelination in the
central nervous system (CNS) accompanied by paralysis
(15). Recently, myelin-glycolipid–reactive T cells have
been found with increased frequency in peripheral blood of
MS patients (16). Although class I and class II MHC-
restricted myelin protein-reactive T cells have been shown
to be involved in autoimmune pathology (14, 17, 18), it is not
known whether CD1d-reactive T cells recognizing myelin
lipids are part of the mature T cell repertoire and might be
targeted to influence the course of demyelination or paraly-
sis. Here we show that sulfatide-reactive CD1d-restricted
T cells represent a distinct population of T cells that infil-
trate into the CNS during EAE and can be appropriately
activated to prevent disease.
 
Materials and Methods
 
Mice.
 
C57BL/6 (BL/6) mice were from Jackson Labs.
CD1d1
 
 
 
/
 
 
 
 and J
 
 
 
18
 
 
 
/
 
 
 
 mutant BL/6 mice originally generated
in the laboratories of Dr. Luc Van Kaer (Vanderbilt University,
Nashville, TN) and Dr. M. Taniguchi (Chiba University, Chiba,
Japan) were provided by Dr. Mitch Kronenberg (LIAI). BL/
6.CGT
 
 
 
/
 
 
 
 mice were provided by Dr. Brian Popko (University
of North Carolina, Chapel Hill, NC). All mice were bred and
maintained in specific pathogen-free conditions in facilities at the
LIAI and TPIMS.
 
Disease Model.
 
EAE was induced in BL/6 mice with
MOG
 
35–55
 
 peptide emulsified in complete Freund’s adjuvant fol-
lowed by injection with the pertussis toxin (MOG
 
35–55
 
/CFA/
PT), essentially as described (19).
 
Reagents.
 
Synthetic 
 
 
 
-GalCer and 
 
 
 
-GalCer were provided
by Dr. Koezuka (Kirin Brewery Co., Tokyo, Japan). Purified
(
 
 
 
99%) myelin-derived lipids, sulfatide, sphingomyelin, and
the gangliosides mono-GM1, GD1a, and GD1b were purchased
from Fluka, Sigma-Aldrich, or Maitreya. All lipids were dis-
solved in vehicle (0.5% polysorbate 20 and 0.9% NaCl solution)
and diluted with PBS for in vitro proliferation and in vivo in-
jections. The V
 
 
 
3
 
 
 
/V
 
 
 
8
 
 
 
 and V
 
 
 
14
 
 
 
 hybridomas were pro-
vided by Drs. S. Cardell (University of Lund), A. Bendelac
(University of Chicago, Chicago, IL) and M. Kronenberg
(LIAI), respectively. All monoclonal antibodies were purchased
from BD Biosciences.
 
Measurement of Proliferative and Cytokine Responses.
 
For pro-
liferative responses, 8 
 
 
 
 10
 
5
 
 splenocytes were cultured in vitro
in the presence of graded concentrations of glycolipids, (1–50
ng/ml for 
 
 
 
-GalCer and 0.5–50 
 
 
 
g/ml for other lipids).
Quantitation of these responses was accomplished by measur-
ing incorporation of [
 
3
 
H]-thymidine as described earlier (19).
For comparison of the proliferative and cytokine secretion pro-
files, splenocytes from naive animals were cultured in the pres-
ence of graded concentrations of sulfatide. Supernatants from
16- or 48-h cultures were used in ELISA assays to measure cy-
tokine secretion. Standard sandwich ELISA and ELISPOT
were used to measure cytokine levels and the frequency of cy-
tokine-secreting cells, using reagents from BD Biosciences as
described (20). In hybridoma assays, IL-2 secretion was deter-
mined in culture supernatants after 16 h incubation with APC
and different glycolipids.
 
Cellular ELISPOT Analysis.
 
IFN-
 
 
 
– and IL-4–producing
cells were enumerated from glycolipid-pulsed lymphocytes iso-
lated from immunized mice by cellular ELISPOT assay as de-
scribed earlier (20). Briefly, splenocytes (5 
 
 
 
 10
 
6
 
 cells/ml) were
cultured for 48 h in 24-well plates either with medium alone or
with sulfatide (40 
 
 
 
g/ml). Millititer HA nitrocellulose plates
(Millipore) were coated overnight at 4
 
 
 
C with anti–IFN-
 
 
 
 or
anti–IL-4 Abs. After blocking coated plates, antigen-stimulated
cells were added at graded concentrations for 24 h at 37
 
 
 
C. The
wells were then incubated with biotin-conjugated anti–IFN-
 
 
 
 or
anti–IL-4 mAbs followed by incubation with avidin peroxidase
(Vector Laboratories). Spots were developed by the addition of
3-amino-9-ethylcarbazole substrate (Sigma-Aldrich) and counted
using a computerized image analysis system (Ligh-tools Research)
and the image analyzer program, NIH Image 1.61.
 
Isolation of Mononuclear Cells from the Liver and CNS.
 
Single
cell suspensions were prepared from liver, brain, and spinal cords
using discontinuous density gradient centrifugation as described
previously (19). Briefly, after whole body perfusion with chilled
PBS infiltrating cells from brain and spinal cord were suspended
in 70% Percoll (Amersham Biosciences) in HBSS and overlaid
with equal volumes of 37 and 30% Percoll, and the gradient was
centrifuged at 500 
 
g
 
 for 15 min. Mononuclear cells were har-
vested from the 37–70% interface and washed in HBSS.
 
Tetrameric mCD1d–lipid Complexes.
 
PE- or Cy-chrome–labeled
mCD1d1–
 
 
 
-GalCer tetrameric complexes were made in a bacu-
lovirus expression system as described previously (19, 21). “Un-
loaded” mCD1d1 tetramers were prepared by preincubating
biotinylated mCD1d protein with vehicle only. To produce self-
lipid–CD1d tetramers, biotinylated mCD1d protein was incu-
bated with sulfatide at a molar ratio of 1:6 for 18–20 h.
 
Intracellular Cytokine Analysis.
 
For intracellular staining, anti–
FcR-
 
 
 
 and neutravidin-treated CNS-infiltrating mononuclear
cells were cultured for 5 h in the presence of Brefeldin A and
permeabilized using Cytofix/Cytoperm Plus™ (BD Biosciences)
and stained using either FITC-labeled anti–IL-4 clone BVD4–
1D11 or FITC-labeled anti–IFN-
 
 
 
 clone XMG1.2 (BD Bio-
sciences). Staining was done in conjunction with anti-TCR
 
 
 
chain antibody (H57–597; BD Biosciences) that reacts with a
common epitope of the 
 
 
 
-chain of the receptor complex on 
 
 
 
-
 
 
 
TCR-expressing T cells of all mouse strains tested, according to
the manufacturer’s protocol. 
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Flow Cytometry.
 
Mononuclear cells suspended in PBS buffer
containing 0.001% NaN
 
3
 
 (wt/vol) and 5% BSA (vol/vol) were
first treated with antibodies against FcR-
 
 
 
 (2.4G2) and then la-
beled with the indicated antibodies. For mCD1d–lipid tetramer
staining, cells were also treated with neutravidin (Molecular
Probes) and then incubated with tetramers for 1 h as described
(19, 21). All FITC-, PE-, Cy-Chrome, and allophycocyanin-
conjugated mAbs were acquired from BD Biosciences. For flow
cytometry staining, 2.5 
 
 
 
g of tetramerized mCD1d was used.
Flow cytometric analysis was performed on a FACSCalibur in-
strument using CellQuest software (Becton Dickinson). In each
flow cytometric staining profile, the percentage of the gated pop-
ulation is shown in the top right corner.
 
Statistical Analysis.
 
Statistical analyses were performed using
 
 
 
2
 
 and student’s 
 
t
 
 tests as appropriate. p-values 
 
 
 
0.05 were con-
sidered statistically significant.
 
Results
 
A CD1d-dependent Immune Response to a Myelin-derived
Glycolipid, Sulfatide.
 
To assess the nature of the response
to self-glycolipids and their dependence on the CD1d anti-
gen presentation pathway, splenocytes from naive wild-
type BL/6 or CD1d
 
 
 
/
 
 
 
 mice were cultured with graded
doses of glycolipids and assayed for proliferation and cyto-
kine secretion (Fig. 1, A and B). Splenic cells from WT but
not from CD1d
 
 
 
/
 
 
 
 mice proliferate and produce both
IFN-
 
 
 
 and IL-4 in response to sulfatide. Proliferation and
cytokine secretion in response to sulfatide were lower in
magnitude than to 
 
 
 
-GalCer, possibly indicating a lower
cell number or lower TCR avidity of sulfatide-reactive T
cells in comparison to the 
 
 
 
-GalCer–reactive V
 
 
 
14 invari-
ant population. The failure of sulfatide to elicit a response
Figure 1. A distinct CD1d-restricted
sulfatide-reactive T cell population in naive
mice. (A) Proliferative response of spleno-
cytes from naive BL/6 or BL/6.CD1d / 
mice in response to an in vitro stimulation
with indicated self-lipids (10  g/ml) or
 -GalCer (10 ng/ml) suspended in PBS/vehi-
cle. Each symbol represents response of an
individual animal in each group (n   4–11),
with the mean proliferative response indi-
cated by a horizontal bar. *P   0.004. (B) In
vitro cytokine and proliferative response
of splenocytes from naive BL/6 ( ) or
BL/6.CD1d /  ( ) mice to a titrated dose of
sulfatide. One of three representative experi-
ments is shown. (C) FACS® analysis of lym-
phocytes from the liver, spleen, and thymus
from BL/6 (CD1d / ) or BL/6.CD1d / 
(CD1d / ) mice after staining with fluo-
resceinated tetramers or anti-NK1.1 mAbs
in conjunction with the anti-TCR  chain
antibody. One of three representative ex-
periments is shown. (D) Flow cytometric
profile of splenocytes from BL/6 mice stained
simultaneously with the CyChrome-labeled
 -GalCer/CD1d tetramers and with the PE-
labeled sulfatide/CD1d tetramers. (E) Flow
cytometric profile of splenocytes from
BL/6 and BL/6.J 18 /  mice stained with
 -GalCer/CD1d tetramers or sulfatide/
CD1d tetramers. 
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in CD1d
 
 
 
/
 
 
 
 mice indicates the requirement for CD1d-
restricted presentation. There were no detectable responses
to other self-glycolipids capable of binding to CD1d mole-
cules, including  -GalCer, sphingomyelin, and GM1.
Sulfatide/mCD1d Tetramer  Cells Are Part of the Naive T
Cell Repertoire. To define the cell population responsible
for the proliferative and cytokine responses to sulfatide, tet-
rameric mCD1d molecules loaded with sulfatide were used
to stain T cells in the thymus, liver, and spleen (Fig. 1 C).
Sulfatide/CD1d tetramer  T cells are predominantly
CD4 CD8  ( 90%) and comprise 5–7% of mononuclear
cells in liver, 0.3–0.5% in thymus, and  0.3–0.7% in
spleen and thus represent  1/3–1/4 the number of  -Gal-
Cer–reactive iNK T cells in BL/6 mice. We found no
staining with CD1d complexes loaded with GM1 (Fig. 1
C), GD1a, GD1b,  -GalCer, or with unloaded tetramers.
There was no significant staining of cells in liver and spleen
from CD1d /  mice with sulfatide or  -GalCer tetramers
(Fig. 1 C, right). Although most sulfatide/CD1d tetramer 
cells in the thymus do not express NK1.1, 25–28% are
NK1.1  in spleen and liver. The relatively lower level of
staining with sulfatide tetramer may indicate a lower TCR
avidity of sulfatide-reactive cells in comparison to the
higher avidity V 14 TCR (22) of the  -GalCer–reactive
population and/or the presence of diverse alkyl chains
within the myelin-derived sulfatide preparation used here.
Indeed the higher molar requirement of lipid to stimulate
sulfatide-reactive T cells compared with V 14  T cells
(Fig. 2, C and D) is consistent with the notion that these
cells bear lower avidity TCR.
Sulfatide-reactive T Cells Are Distinct and Do Not Overlap
with the  -GalCer–reactive Invariant T Cell Population. To
determine whether sulfatide-reactive T cells are part of the
V 14 iNK T cell population or represent a distinct CD1d-
restricted T cell repertoire, splenic cells were simulta-
neously stained with  -GalCer/CD1d tetramer conjugated
to CyChrome and sulfatide/CD1d tetramer conjugated to
PE, and analyzed by flow cytometry (Fig. 1 D). A clearly
distinct and nonoverlapping staining profile with the two
tetramers indicates that sulfatide-reactive cells belong to a
different subset of T cells. The difference in T cell reper-
toire between the sulfatide- and  -GalCer–reactive T cells
is further confirmed by the presence of sulfatide/CD1d but
not  -GalCer/CD1d tetramer  cells in J 18 /  mice (Fig.
1 E). These mice lack  -GalCer–reactive iNK T cells ow-
ing to the absence of the J 18 gene segment used by the
invariant V 14 TCR (23).
CD1d-restricted V 3/V 8  NK T Cells Do Not Recognize
Sulfatide. A minor autoreactive CD1d-dependent NK T
cell population has been shown to utilize semiinvariant
TCRs encoded by the TCR V 3 or V 8 gene segments
(24, 25). Although sulfatide-reactive T cells are distinct from
the invariant V 14  T cell population, we wanted to exam-
ine whether the V 3 or V 8  subsets of NK T cells are part
of the sulfatide-reactive population. To avoid background
staining problems and nonavailability of an anti-TCR mAb
capable of staining V 8  T cell subset, we have directly an-
alyzed several V 3  and V 8  NK T cell hybridomas for
their ability to secrete IL-2 in response to sulfatide. As
shown in Fig. 2 E, none of these hybridomas secretes IL-2
upon stimulation in the presence of CD1d  APC and sul-
Figure 2. Sulfatide-reactive T cell hyridomas stain with sulfatide/
CD1d tetramer and secrete IL-2 in response to sulfatide in a CD1d-
dependent manner. A representative T cell hybridoma reactive to sulfatide
(Hy19.3) (B and D) and a  -GalCer–reactive hybridoma (Hy1.2) (A and
C) were stained with sulfatide/CD1d or  -GalCer/CD1d tetramers and
analyzed by FACS®. Unloaded tetramer or GM1-filled tetramer staining
is shown by dotted lines. For IL-2 secretion assay, hybridomas (50,000
cells/well) were incubated with irradiated (3000R) splenocytes (400,000
cells/well) from wild-type C57BL/6 (BL/6) or CD1d /  BL/6 (CD1KO)
mice in the absence or presence of graded concentrations of  -GalCer
or sulfatide, as shown. For blocking of CD1d-dependent presentation,
10  g/ml of anti-CD1d mAb (1B1 [47]) or an isotype-matched mAb
(IgG2b; BD Biosciences) was added during the incubation period. IL-2
secretion levels by Hy19.3 in response to plate-bound anti-CD3 were
1/8–1/10 that of Hy1.2. Concentration of IL-2 in the supernatants is
shown. (E) The CD1d-restricted V 3  (A11, 24, IF4), V 8  (B11, 49),
and V 4  (68) T cell hybridomas were incubated with irradiated CD1d 
splenocytes in the presence of graded concentrations of sulfatide, as
above. Concentration of IL-2 in the supernatants is shown. All of the
hybridomas responded well to plate-bound anti-CD3.Jahng et al. 951
fatide, although they are able to secrete IL-2 in response to
the plate-bound anti-CD3. None of the V 3  or V 8  hy-
bridomas stained with the sulfatide/CD1d tetramer.
Sulfatide-reactive T Cell Hybridomas Stain with Sulfatide/CD1d
Tetramer and Secrete IL-2 in a CD1d-dependent Manner. To
further examine the presence of sulfatide-reactive T cells at
the single cell level, newly established T cell hybridomas and
CD1d-restricted autoreactive hybridomas generated earlier
(24, 25) were analyzed using staining with specific CD1d
tetramers and IL-2 secretion in response to glycolipids. A
representative sulfatide-reactive T cell hybridoma (Hy19.3,
V 14 ) stains with sulfatide/CD1d tetramer and not  -Gal-
Cer tetramer. In contrast, a  -GalCer–reactive T cell hy-
bridoma (Hy1.2, Va14 ) stains with  -GalCer/CD1d tet-
ramer but not with sulfatide tetramer (Fig. 2, A and B).
These hybridomas do not show any significant staining with
either unloaded or GM1-loaded tetramer. Furthermore, the
sulfatide-reactive hybridoma secretes IL-2 in the presence of
syngenic CD1d  APC (BL/6) pulsed with sulfatide but not
with  -GalCer. In contrast, the  -GalCer–reactive hybrid-
oma responds to  -GalCer but not to sulfatide.
To further examine the MHC restriction of sulfatide-
reactive T cells, IL-2 secretion by the T cell hybridoma was
analyzed in the presence of sulfatide-pulsed APC from
CD1d /  mice and in the presence of a blocking anti-CD1
mAb. As shown in Fig. 2, C and D, IL-2 secretion was not
detected when APC from CD1d /  (CD1KO) mice were
used. Additionally, cytokine secretion was almost completely
blocked in the presence of blocking anti-CD1d mAb and
sulfatide-pulsed APC from CD1d /  (BL/6) mice. Further-
more, IL-2 secretion was also detected when CD1d-trans-
fected A20 cells were used as APC (unpublished data). These
data clearly show that V 14  T cells recognize sulfatide in
the context of CD1d molecules.
Absence of Endogenous Sulfatide Results in a Severalfold In-
crease in Sulfatide/CD1d Tetramer  Cells. CD1d-reactive
V 14 invariant T cell development is thymus dependent
(26). Recent studies suggest that maturation of these cells
is subject to positive selection and that the early steps of
this process might be similar to those proposed for the
classical MHC I and II–restricted T cells (10). Because
CD1d self-glycolipid ligands have not been well defined,
it is not yet known whether CD1d-restricted T cells are
also subject to thymic negative selection. To determine
whether the sulfatide-reactive T cell repertoire is altered
in the absence of the endogenous glycolipid, thymocytes
from mice functionally deficient in the gene encoding
the enzyme UDP-galactose ceramide galactosyltransferase
(CGT) (27), which is required for myelin galactolipid syn-
thesis, were analyzed using lipid tetramers (Fig. 3). These
mice lack all galactolipids, including sulfatide, and exhibit
tremor and paralysis and do not survive beyond 3–6 wk of
age. Sulfatide/CD1d- but not  -GalCer/CD1d-tetramer 
T cells are increased  10-fold in the thymus of CGT / 
mice (3.21%) compared with WT mice (0.28%). Al-
though, sulfatide/CD1d tetramer  cells appear to be
TCRlow, their CD4 and CD8 expression is similar to
those of  -GalCer/CD1d tetramer  cells. These data sug-
Figure 3. Sulfatide/CD1d tetramer  cells are increased
severalfold in mice lacking the CGT. Thymocytes pooled
from three age-matched, naive BL/6 or BL/6.CGT / 
mice were stained with  -GalCer/CD1d or sulfatide/
CD1d tetramers in conjunction with anti-NK1.1, anti-
TCR , anti-CD4, or anti-CD8 mAb and analyzed by
FACS®. The CD4 and CD8 staining profiles of thymocytes
were similar in both sets of mice. This is representative of two
independent experiments.Sulfatide-reactive T Cells in Experimental Autoimmune Encephalomyelitis 952
gest that sulfatide-reactive T cells may be subject to nega-
tive selection in the thymus. This is consistent with recent
reports suggesting negative selection of classical V 14 
iNK T cells using the nonmammalian glycolipid  -Gal-
Cer (28, 29).
Selective Enrichment of IFN- –secreting Sulfatide-reactive T
Cells in the CNS During EAE. Although sulfatide is
present in most membranes, it is particularly enriched in
the myelin sheath, which becomes the target of autoim-
mune inflammation during EAE. To determine whether
sulfatide-reactive T cells are present in CNS-infiltrating
lymphocytes, mononuclear cells isolated from the brain and
spinal cord of BL/6 mice with ongoing disease were ana-
lyzed following staining with tetramers and compared with
cells in liver and spleen (Fig. 4, A and D). Sulfatide-reactive
T cells accumulate in the CNS (3.8   1.4%) selectively
during clinical EAE and are not detectable in naive mice,
or of particular interest, in immunized mice that do not de-
velop clinical paralysis. In contrast,  -GalCer–reactive T
cells constitute only a minor part (0.96   0.13%) of the
CNS infiltrate in diseased animals. A similar increase in the
number of sulfatide/CD1d tetramer  T cells is also found
Figure 4. Sulfatide-reactive T cells infiltrate the CNS
during the course of EAE. (A) Mononuclear cells from the
CNS of diseased BL/6 mice (n    7) were pooled and
stained with the indicated lipid/CD1d tetramers and analyzed
by FACS®. A representative of two experiments is shown.
(B) To analyze the TCR V  gene usage, sulfatide/CD1d
tetramer  cells were stained with various anti-V  mAbs. A
typical positive and negative staining profile is shown. (C) Ex
vivo intracytoplasmic staining of the CNS-infiltrating cells
for IFN-  and IL-4. (D) The percentages of  -GalCer– or
sulfatide-reactive T cells in spleen, liver, and the CNS of
naive animals or mice with EAE were determined by
FACS® analysis. The plot represents the averaged data of
three independent experiments (a total of 19 mice in each
group). *P   0.0001.Jahng et al. 953
in the CNS tissue from B10.PL mice with myelin basic
protein (MBP)-induced EAE (unpublished data).
To determine their TCR V  repertoire, sulfatide/CD1d
tetramer  T cells were also stained with a set of available anti-
TCR V -chain mAbs (BD Biosciences). Sulfatide-reactive T
cells infiltrating CNS predominantly utilize TCR V 8 and
V 6 and not the V 2 or V 7 gene segments used by iNK T
cells (Fig. 4 B). There was no significant staining with other
V -specific antibodies analyzed (see Materials and Methods).
Thus, only TCR V 8 usage is shared between  -GalCer–
and sulfatide-reactive T cells in BL/6 mice.
Since sulfatide-reactive T cells accumulate in the CNS in
diseased animals and show an activated phenotype, we next
determined the secretion of type 1 (IFN- ) or type 2 (IL-4)
cytokines by the infiltrating cells directly ex vivo using in-
tracytoplasmic staining in the absence of in vitro stimula-
tion with sulfatide. Fig. 4 C shows that the CNS-infiltrat-
ing cells secrete only IFN- , with undetectable levels of
IL-4. This may be related to the proinflammatory milieu of
CNS in diseased mice.
Increase in Sulfatide-reactive T Cells After Immunization with
Sulfatide. Myelin protein–reactive class I or class II–
restricted T cells have been shown to expand in the periph-
ery after immunization with myelin-derived proteins, for
example, MBP. A sensitive ELISPOT assay has been suc-
cessfully used to examine the frequency of these cells under
different conditions of priming (20, 30). Since sulfatide-reac-
tive T cells are present in small numbers, especially in spleen,
we have used cytokine ELISPOT assays to examine the fre-
quency of these T cells in splenocytes after immunization
with sulfatide. As shown in Fig. 5, immunization of mice
with sulfatide expands a T cell population in splenocytes that
produces IFN-  and IL-4 in response to an in vitro recall
with sulfatide. The frequency of sulfatide-reactive T cells is
three- to fourfold higher in sulfatide-immunized mice com-
pared with mice immunized with mono-GM1 or PBS.
These data indicate an expansion of peripheral myelin-gly-
colipid–reactive T cells after immunization with the self-gly-
colipid and parallels that of myelin protein–reactive T cells
after challenge with myelin-derived proteins.
CD1d-dependent Prevention of EAE by Sulfatide. i.v. de-
livery of  -GalCer results in the rapid activation of iNK T
cells followed by the disappearance of  -GalCer tetramer 
cells and significant protection from antigen-induced EAE
(19, 31). To determine whether in vivo activation of sul-
fatide-reactive T cells influences the course of EAE, both
wild-type and CD1d /  mice were given 20  g of sulfatide
in vehicle or vehicle only and at the same time challenged
with MOG35–55/CFA/PT for the induction of EAE (Fig. 6
and Table I). Coinjection with sulfatide results in significant
protection from disease that is dependent on the presence of
the CD1d molecules, since CD1d-deficient animals are not
protected. In contrast, injection with other self-glycolipids
has no effect on the course of EAE (Table I). Mice injected
with sulfatide alone in the presence of CFA/PT immuniza-
tion do not develop clinical signs of disease and lack detect-
able numbers of sulfatide/CD1d tetramer  cells in the
CNS. Similarly, a single injection of sulfatide into B10.PL
mice also prevents MBPAc1-9–induced EAE in a CD1d-
dependent fashion (not depicted). Timing of injection with
 -GalCer in relation to the immunization with MBP or
MOG has been shown to influence the efficacy of protec-
tion from EAE (19). To examine this issue for sulfatide,
mice were injected either 1 wk before or 1 wk after the
MOG/CFA/PT immunization for the induction of disease.
As shown in Table I, in both immunization protocols mice
were significantly protected from EAE.
Protection from Disease Correlates with Inhibition of Cytokine
Secretion by MOG-reactive T Cells. The mechanism of
iNK T cell–mediated protection from autoimmune diseases
(19, 31–35) has been attributed either to immune deviation
or to inhibition of the differentiation of effector functions
of pathogenic self-protein–reactive T cells. To gain insight
into the mechanism of sulfatide-induced modulation of
EAE, levels and frequency of both IFN- – and IL-4–
secreting MOG-reactive T cells were determined in drain-
ing LN cells using ELISA and ELISPOT analysis, respec-
tively, in groups of MOG35–55-immunized animals coinjected
either with sulfatide or PBS only (Fig. 7). In sulfatide-
injected mice, the numbers of both IFN- – and IL-4–secret-
ing cells and levels of cytokine secretion by MOG35–55-
Figure 5. Increased frequency
of cytokine-secreting, sulfatide-
reactive lymphocytes after immu-
nization with sulfatide. Groups of
mice (two in each) were immu-
nized in complete Freund’s adju-
vant with 20  g of sulfatide or
with 20  g of mono-GM1 or
with PBS/vehicle alone. 10 d
later,  splenocytes were isolated,
recalled in vitro with sulfatide, and
subjected to ELISPOT analysis as
described in Materials and Meth-
ods. The average number of spots/
106 spleen cells for both IFN- 
and IL-4 in each group is shown.
Figure 6. Immunization of
mice with sulfatide protects mice
from EAE. In a representative
experiment, groups of female
BL/6 or BL6.CD1 /  mice
were immunized i.p. with 20  g
of sulfatide ( ) (n   4) or with
PBS/vehicle alone ( ) (n   4)
at the time of disease induction
with MOG35–55/CFA/PT. The
mean clinical disease course of
mice in each group is shown.
The summary of all independent
experiments is provided in Table I.
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reactive T cells are diminished significantly. There is no
significant difference in response to a polyclonal stimulus,
protein-purified derivative of mycobacterium.
Discussion
This study demonstrates that sulfatide is a self-glycolipid
ligand recognized by a population of CD1d-restricted T
cells that is distinct from the invariant V 14  NK T cell
population and is part of the mature naive T cell repertoire.
Sulfatide-reactive T cells also appear to be distinct from
other CD1d-restricted T cell populations expressing semiin-
variant V 3.2-J 9 or V 8 TCRs. Sulfatide-reactive but not
 -GalCer–reactive T cells are increased severalfold within
the CNS during EAE. Notably, treatment of mice with sul-
fatide prevents antigen-induced EAE by inhibiting the ef-
fector function of self-protein–reactive pathogenic T cells.
Several observations demonstrate the distinctiveness of
sulfatide-reactive T cells from the  -GalCer–reactive
V 14  iNK T lymphocytes. (a) These are two nonover-
lapping populations, as revealed by simultaneous staining
with sulfatide/CD1d  and  -GalCer/CD1d tetramers; (b)
sulfatide/CD1d tetramer  cells are present in J 18 / 
mice, which lack iNK T cells, showing that sulfatide-reac-
tive T cells do not use the invariant TCR using the V 14-
J 18 gene segment. This is further confirmed using sul-
fatide-reactive T cell hybridomas, which are also V 14
negative. (c) There is a differential increase in the fre-
quency of these cells in the CNS during EAE and in galac-
tolipid-deficient mice; (d) though these cells share the
TCR V 8 usage, sulfatide-reactive T cells do not use
theV 2 or V 7 chains predominantly used by the classical
V 14  iNK T cells; (e) higher percentages of sulfatide- but
not  -GalCer–reactive T cells in CGT /  mice lacking
self-galactolipids indicate that these two populations may
recognize different lipids in vivo and that at least some
CD1d-restricted T cells, like the classical MHC I– or II–
restricted T cells, may be subject to central tolerance; (f)
 -GalCer–reactive V 14  T cell hybridomas do not secrete
IL-2 in response to sulfatide, whereas sulfatide-reactive
V 14  hybridomas respond to sulfatide and are nonre-
sponsive to  -GalCer or to other self-glycolipids, such as
 -GalCer, sphingomyelin, or GM1. Furthermore, sul-
fatide-reactive T cells are also different from the other
CD1d-restricted T cells that use semiinvariant TCR. These
studies show the diverse nature of the CD1d-restricted T
Table I. Specificity of Protection from EAE After Injection with Myelin-derived Sulfatidea
Treatment MOG35-55/CFA/PT
Incidence 
(no. of mice [maximum score]) Mean maximum score  Mean day of onset 
C57BL/6
PBS  
24/24
[2(2), 7(3), 12(4), 3(5)] 3.7 12.9
Sulfatide (d 0)   
13/23b
[10(0), 8(2), 1(3), 1(4)] 1.8   18
Sulfatide (d   7)   
4/6
[1(2), 3(3)] 1.9 15.4
Sulfatide (d   7)  
2/6
[2(2)] 0.7 16.1
GM1  
11/11
[2(2), 5(3), 4(4)] 3.2 16
Sphingomyelin   
4/4
[2(2), 2(4)] 3.0 13.3
  -GalCer   
6/6
[1(2), 1(3), 2(4), 2(5)] 4.0 14.3
Sulfatide   0/5
C57BL/6 – CD1dKO
PBS   
 7/7 
[2(2), 2(3), 2(4), 1(5)] 2.9 13
Sulfatide  
8/8
[1(2), 3(3), 3(4)] 3.0 12.8
aGroups of mice were injected i.p. with 20  g of sulfatide, mono-GM1, sphingomyelin,  -GalCer, or PBS/vehicle only. On the same day (d 0),
injected mice were immunized s.c. with MOG35-55/CFA/PT for the induction of EAE. Sulfatide was also injected either 7 d prior to (d   7) or after
(d   7) the immunization with MOG35-55/CFA/PT. The incidence, mean maximum score, and mean day of onset of clinical EAE is shown.
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cell repertoire and demonstrate the feasibility of using self-
glycolipid–CD1 tetramers as a powerful means for investi-
gating their involvement in a variety of autoimmune and
infectious diseases.
Lack of detectable immune reactivity to other myelin-
derived lipids such as mono-GM1, GD1a, and GD1b may
reflect their low availability for a CD1d-dependent display
or their cryptic T cell repertoire. Consistent with studies in
humans (13), our data suggest that the sulfate moiety and
not simply the negative charge in sulfatide is required for
interaction with the TCR. Thus, we have found no re-
sponse to  -GalCer lacking the sulfate group or to mono-
GM1, which contains a negatively charged residue sialic
acid, despite the fact that both lipids are able to bind to
CD1d molecules (36). Further studies using synthetic lipids
are required to determine the precise role of saturated ver-
sus unsaturated acyl chains of different lengths (C16–24)
present in myelin-derived sulfatides in binding either to
CD1d molecules or to the TCR.
Accumulation of sulfatide-reactive T cells during the
process of autoimmune demyelination in CNS tissue,
which is enriched in this glycolipid antigen, suggests that
after local inflammation sulfatide may be presented by resi-
dent or circulating CD1d  APC. Increased levels of CD1d
expression in the macrophage/microglia fraction of the
CNS during EAE in mice (unpublished data) and CD1d-
like proteins in guinea pigs with EAE have been found re-
cently (37). Similarly up-regulation of CD1b in chronic-
active MS lesions but not in silent lesions of the brain has
been reported (38). Thus, after myelin destruction owing
to either viral infection or demyelination, APCs in the
CNS may present both glycolipids and proteins (39). Our
findings demonstrating the enrichment of sulfatide-reactive
T cells in target tissue further suggest that determinant
spreading (40) during chronic autoimmune responses may
involve T cells reactive not only to different protein anti-
gens but also to glycolipids. Consistent with our data in
EAE, the frequency of sulfatide-reactive, CD1-restricted T
cells secreting IFN-  has been shown to be significantly
higher in active MS patients compared with normal indi-
viduals (Duda et al., personal communication).
It is becoming increasingly clear that similar to patho-
gen-derived protein antigens, microbial lipids can be pre-
sented in the context of CD1 molecules, for example, after
Mycobacterial infection (5, 41). Consistent with this, ex-
pansion of CD1d-reactive invariant V 14  T cells (42) or a
noninvariant CD1d-restricted T cell population (43) in
murine models of colitis and acute hepatitis, respectively,
has been reported recently. Additionally, the presence of
sulfatide-reactive T cells in the mature naive repertoire and
their enrichment in a target tissue also mimic insulin and
myelin proteolipid protein-reactive T cells in diabetes
and EAE, respectively, (44, 45) and may further indicate
parallels between classical MHC-restricted and CD1d-
restricted T cells. This is also reflected in data showing in-
creased frequency of sulfatide-reactive T cells in peripheral
lymphoid organs after immunization of sulfatide.
Even though a detailed mechanism of sulfatide-medi-
ated modulation of EAE remains to be determined, our
study demonstrates that early administration of sulfatide
results in the inhibition of both type 1 and 2 cytokine se-
cretion by pathogenic myelin protein–reactive T cells and
is sufficient to prevent clinical disease symptoms. This may
be similar to the inhibition of diabetogenic T cell differen-
tiation by the invariant V 14  T cell population in the ab-
sence of activation by  -GalCer (35) and is distinct from
the proposed immune deviation of pathogenic T cells after
their in vivo activation with  -GalCer resulting in protec-
tion from diabetes (32, 33) and EAE (19, 31, 46). These
earlier studies suggested that Th2 cytokines, such as IL-4
and IL-10, are likely to be involved in  -GalCer–medi-
ated modulation of autoimmune disease. In contrast, our
preliminary data suggest that these Th2 cytokines are not
involved in sulfatide-mediated protection from EAE, since
administration of anti–IL-4 mAb had no effect on this
modulation (unpublished data). It is notable that injection
of sulfatide at different times relative to the immunization
with MOG peptide results in significant protection from
EAE (Table I). Furthermore our preliminary experiments
suggest that an appropriate dose of sulfatide injected dur-
ing ongoing EAE is effective in reversing disease. These
findings, along with the studies showing an increased fre-
quency of sulfatide-reactive CD1-restricted T cells in MS
patients, demonstrate that in addition to myelin protein–
reactive class I or II MHC-restricted T cells, myelin-gly-
colipid–reactive, CD1d-restricted T cells represent poten-
Figure 7. Inhibition of cytokine secretion by MOG-reactive T cells after
coinjection with sulfatide. Groups of female BL/6 mice were coinjected
i.p. with either 20  g of sulfatide in PBS/vehicle or PBS/vehicle alone at
the time of s.c. challenge with 100  g MOG35–55 in CFA. 10 d later, LN
cells were cultured with graded concentrations of MOG35–55 or protein-
purified derivative of Mycobacterium (PPD) for the measurement of
proliferation and cytokine secretion by ELISA and ELISPOT analysis.
Averaged responses within the group are plotted. A representative of
three independent experiments is shown. *P-value   0.004.Sulfatide-reactive T Cells in Experimental Autoimmune Encephalomyelitis 956
tial targets for intervention in human autoimmune demy-
elinating diseases.
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